← Back to Search

A Prospective Natural History Study in Uveal Melanoma

Sydney, Australia
N/A
Recruiting
Led By Richard D. Carvajal, MD
Research Sponsored by Columbia University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to five years
Awards & highlights
No Placebo-Only Group

Summary

The overall objective of this proposal is to develop and utilize a multicenter UM registry that will, in a longitudinal fashion, capture prospective data in order to characterize the natural history of UM and provide data that will be used to support the development of novel therapies for this disease. The care of patients with UM requires a multi-disciplinary team of physicians that commonly requires the involvement of both radiation oncology and interventional radiology, and is typically directed by an ophthalmologic oncologist at time of initial diagnosis of primary disease. Overall management is transitioned to a medical oncologist when distant recurrence is identified. In the case that a patient presents with metastasis at the time of diagnosis, a medical oncologist typically directs overall management. The management of surveillance for the development of metastasis following the treatment of primary disease is variable and, if performed at all, is managed by either an ophthalmologic oncologist or medical oncologist. Thus, the successful development of a registry that aims to capture the data regarding the full natural history of UM requires a collaborative effort including leaders from both the UM ophthalmologic oncology and medical oncology fields. To this end, the investigators have built an initial consortium of key ophthalmologic oncology and medical oncology leaders from multiple major UM centers in the United States.

See full description
Eligible Conditions
  • Uveal Melanoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to five years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to five years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Overall Survival Rate
Overall Survival Rate of Patients with Uveal Melanoma
Relapse-free Survival Rate

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Find a Location

Closest Location:Thomas Jefferson University Hospital· Philadelphia, PA· 416 miles

Who is running the clinical trial?

Columbia UniversityLead Sponsor
1,521 Previous Clinical Trials
2,829,529 Total Patients Enrolled
Richard D. CarvajalLead Sponsor
3 Previous Clinical Trials
73 Total Patients Enrolled
Richard D. Carvajal, MD4.210 ReviewsPrincipal Investigator - Columbia University
Columbia University
Shaheer Khan, DOPrincipal InvestigatorColumbia University
1 Previous Clinical Trials
42 Total Patients Enrolled
~172 spots leftby Jul 2026